Key points are not available for this paper at this time.
Introduction/Background We aimed to study the impact of the COVID-19 pandemic on patient and treatment characteristics of both endometrial and ovarian cancer in the Netherlands. Methodology Data of the Netherlands Cancer Registry was used to perform a retrospective cohort study on women of 18+ years diagnosed with invasive endometrial (EC) or epithelial ovarian cancer (OC) in the period 2017–2021. Patient characteristics, tumour stage at diagnosis, types of treatment, waiting periods for treatment and referral patterns in the period before the COVID-19 pandemic (BC; 2017–2019), during the pandemic (2020) and after the first year of the pandemic (2021) were assessed. Results No stage shift was noticed for both EC and OC. For EC, fewer patients received surgery (87.6% BC, 84.6% 2020, 85.8% 2021, p=0.02) and more patients received primary hormone therapy in 2020 and 2021 compared to the period BC (4.2% BC, 5.9% 2020, 5.6% 2021, p=0.03). The waiting time between the first consultation and time of first surgery was shorter in 2020 and 2021 (pConclusion Although the COVID pandemic had a profound impact on the society and the delivery of health care in general, there was a minimal impact on tumour characteristics associated with outcome, in patients with EC and OC during the pandemic and after the first year following the pandemic in the Netherlands. It will be a few years before the impact of the COVID-19 pandemic on progression-free survival and overall survival can be assessed. Disclosures The authors do not have any conflict of interest to declare.
Oymans et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: